



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 652 012 A1**

12

EUROPEAN PATENT APPLICATION

21 Application number: 93308852.8

51 Int. Cl.⁸: A61K 31/70, A61K 31/195

22 Date of filing: 05.11.93

43 Date of publication of application:
10.05.95 Bulletin 95/19

84 Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

71 Applicant: Naito, Albert
c/o Edward E. Roberts,
200 West Santa Ana Boulevard,
Suite 660
Santa Ana,
California 92701 (US)

72 Inventor: Naito, Albert
c/o Edward E. Roberts,
200 West Santa Ana Boulevard,
Suite 660
Santa Ana,
California 92701 (US)

74 Representative: Sturt, Clifford Mark et al
J. MILLER & CO.
34 Bedford Row
Holborn
London WC1R 4JH (GB)

54 Combination of sugars with amino acids and other drugs.

57 A material which has the ability to effect its passage, at least in part, and the ability to transport other materials through the blood-brain barrier which includes any one or more pure sugars or pure amino sugars from the group consisting of meso erythritol, xylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, myo-inositol, L(-) fructose, D(-) mannitol, sorbitol, D(+) glucose, D(+) arabinose, D(-) arabinose, cellobiose, D(+) maltose, D(+) raffinose, L-(+)-rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, L(-) lyxose, D(+) glucosamine, D mannosamine, and D galactosamine; and any one or more amino acids from the group consisting of arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, glutamine, lysine, tryptophan, tyrosine, valine, and taurine. For use in the research or treatment of a subject that material is combined with one or more of the substances beta carotene, xanthophyll,

lecithin, calcium, somatostatin, vasopressin, endorphin, enkephalin, acetyl-L-carnitine, GABA, dynorphin, L-tryptophan, choline, thiamine, pyridoxine, niacin, L-arginine, hydroxyproline, NGF, methionine, cystine, potassium, phosphorus, chlorine, sodium, vitamins A, B, C, D and E, tricalcium phosphate, omega 3 and omega 6 both of which are high linolenic acids, oats, rice, apple fiber, acidophilus, and selenium.

EP 0 652 012 A1

This invention relates to materials and methods for passing, and transporting other substances, through the blood-brain barrier.

Background of the Invention

If one accepts the premise that most physiological functions are controlled by the brain and the medium of that control is electrical signalling as an incident to chemical activity in the brain, then it seems logical to conclude that an absence in the brain of the chemicals required for that activity can result in signal failure and consequent physiological disfunction. It is possible also to conclude that a genetic trait which interferes with such chemical activity can result in signal failure and disfunction. It is also possible to conclude that the presence of a given substance in the brain may interfere chemically with the proper generation of control signals.

Such considerations, the search for an understanding of the mechanism of drug dependence, drunkenness, Alzheimer's disease, schizophrenia and other disorders, some associated with the brain and others apparently not, have lead many researchers to look for a relation between such disorders and availability of chemicals in the brain. The medical literature includes descriptions that comparison of brain tissue of persons who succumbed to a given disease with that of persons who died of unrelated causes suggest a relation between a given chemical and the disease. Thus lack of lithium has been mentioned in connection with schizophrenia and lack of neuropeptides has been mentioned in connection with Alzheimer's disease.

Studies in that area, the chemical treatment of brain cancers, and other studies and procedures are hampered by the difficulty in introducing chemicals into the brain because of what is commonly called the blood-brain barrier. The blood vessels of the brain are formed by cells which are more closely packed than are the vessels elsewhere in the body. That fact and the action of the astrocyte cells account for the fact that many materials are difficult to introduce into the glia of the brain. In some cases the only way that researchers had of getting those materials was to form a hole in the subject's skull and inject the desired material into the brain.

This invention relates to the transportation of material through that blood-brain barrier.

It is an object of the invention to provide novel substances and methods which are useful in conducting research with animal and human subjects into the causes and cure of certain disorders and for the treatment of those disorders.

A related object is to provide substances of that kind which can be utilized by ingestion by a

test subject or patient.

Another object is to provide a vehicle and a method for transporting substances across the blood-brain barrier.

Another object is to provide particular substances which are suitable for the study, and in some cases the treatment, of specific disorders. One of those disorders is loss of hair.

One related object is to provide a substance which, at least for some subjects, has the effect of restoring hair.

These and other objects and advantages of the invention which will hereinafter appear, are realized by the provision of materials which appear to pass through the blood-brain barrier and are capable restoring impeded neuro-transmitter function and apparently of transporting other materials through the barrier or at least facilitating their utilization in the chemical processes of the body. The material that provides those actions is a combination of one or more of a number of "pure" sugars and or pure amino sugars from the group consisting of one or more of a number of amino acids. The sugars are meso erythritol, xylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, myo-inositol, L(-) fructose, D(-) mannitol, sorbitol, D(+) glucose, D(+) arabinose, D(-) arabinose, cellobiose, D(+) maltose, D(+) raffinose, L(+) rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, L(-) lyxose, D(+) glucosamine, D mannosamine, and D galactosamine. The term "pure" as applied to sugar herein means crystalline purity, 93 to 100 percent pure. The requirement for high purity is based upon both a need for purity and the fact that the character of impurities is unknown and some can negate the effectiveness of the sugar or the amino acids.

The amino acids are glutamine, lysine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and taurine. The amino acids may be those found in common foodstuffs such as orange juice, clam chowder, soy bean soup, sheep milk, and others, but for uniform and more predictable result it is preferred that the amino acid be incorporated in pure crystalline form.

Both the proportions in which those materials are combined, and of any added test substances materials, and the quantity of the combination varies with the nature and weight of the test subject. In the case of humans an excessive amount of any of the listed sugars can cause nausea, heat sensation, sleepiness, flushing and ringing of the ears. More than 6 grams of sugar at one time may produce the adverse side effects listed above. Except that excess amounts of amino acid may have

harmful effect on subjects afflicted with certain illness, there appears to be no upper limit to the amount of amino acid that is safely ingested at least by humans.

In attempting to apply the base material to the treatment of alcohol induced drunkenness in humans it was discovered that certain proportions and dosages appear to be both effective to restore motor functions in humans and to be safe for human consumption. The same proportions of sugar and amino acids, and the same dosage in combination with beta carotene have been found to be effective in arresting hair loss and in restoring hair growth. However, different proportions and dosages are preferred in other cases. Drunkenness and hair loss occur in primarily in adults. The invention is applicable to humans and animals of various sizes. The base materials is a combination of sugar and amino acid which is effective to permit transportation of other materials into the glia of the brain past the blood brain barrier. The preferred dosage is, in general, the minimum amount of base material which permits such transportation, one eighth gram of sugar and 10 to 50 milligrams of amino acid is probably the minimum for adults and medium to large animals when the amount of material to be transported is minimal. In most cases it will be desirable to transport more than minimal quantities, the actual amount being related to the subject's weight. The examples set out below assume a weight range which extends from less than a pound for small animals and four pounds in the case of premature human infants to 350 pound, active athletes.

That the base material or some component of it, after having been ingested and entering the blood stream, or having been introduced directly into the blood stream, does actually cross the blood-brain barrier is most readily shown in a test of a person whose motor functions have been very obviously impaired by ingestion of alcohol. Ingestion by that subject of the base material has the effect of restoring the subject's motor functions in a manner of seconds notwithstanding that the alcohol level in the subject's blood remains high.

Evidence has been found that ingesting other substances with the basic combination of sugar and amino acid so that they coexist in the blood stream can result in facilitation of the use of the added material by the body. In one example, adding beta carotene, or xanthophyll, has the effect of increasing the growth of hair and of replacing grey-ness with original hair colour without yellowing the skin. The chemistry of hair restoration by the addition of beta carotene is not known. The fact that it produces the result without the inclusion of carcinogenic material makes it useful for treatment of baldness and certainly useful as a research ma-

terial. Usefulness, at least as a preferred test or research material, is true too of other combinations of specific substances, lecithin, calcium, somatostatin, vasopressin, acetyl-L-carnitine, GABA, dynorphin, vitamins, electrolytes and various minerals and other materials with the base sugar and amino acid materials.

The basic material of the invention is one that passes the blood brain barrier and which has the ability to transport other materials across that barrier. It comprises the combination of one or more of a number of "pure" sugars or "pure" amino sugars with one or more of a number of amino acids. The sugars are meso erythritol, zylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, myo-inositol, L(-) fructose, D(-) mannitol, sorbitol, D(+) glucose, D(+) arabinose, D(-) arabinose, cellobiose, D(+) maltose, D(+) raffinose, L(+)rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, and L(-) lyxose. The term "pure" as applied to sugar herein means crystalline purity, 93 or more percent pure. The amino sugars are D(+) glucosamine, D mannosamine, and D galactosamine. Here-in-after the amino sugars are included in the term "sugar." The requirement for high purity is based upon both a need for purity and the fact that the character of impurities is unknown and some can negate the effectiveness of the sugar or the amino acids.

The amino acids are glutamine, lysine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and taurine. The amino acids may be those found in common foodstuffs such as orange juice, clam chowder, soy bean soup, sheep milk, and others, but for uniform and more predictable result it is preferred that the amino acid be incorporated in pure crystalline form.

In the case of research on human subjects and in the treatment of human subjects, the preferred form of the invention is the combination in the base material of any one or more of the listed sugars and any one or more of the listed amino acids in a quantity such that for each measure of the sugar between 1.25 and 6 grams there is an accumulation of effective amounts to a total of about 480 milligrams or more.

As indicated above, no upper limit to the permissible amount of amino acid has been found. However, medical authorities recommend that persons with certain kinds of ailments avoid ingesting massive doses of amino acid.

The quantity above which additional quantities of amino acids have no effect when combined with 1.25 to 6 grams of sugar was found to be between 2000 and 3000 mg when the objective was to

restore motor functions to drunken subjects. No such threshold of effectiveness has been found for other applications. The lower limit for observable beneficial result is very low, five to ten milligrams of amino acid. Within the list of amino acids, arginine, tryptophan and tyrosine are preferred.

Example of Base Material

Example 1. The combination of from about 0.2 grams to six grams of pure sugar selected from, or consisting of a combination of sugars from, the group consisting of meso erythritol, zylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, myo-inositol, L(-) fructose, D(-) mannitol, sorbitol, D(+) glucose, D(+) arabinose, D(-) arabinose, cellobiose, D(+) maltose, D(+) raffinose, L(+)-rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(-) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, L(-) lyxose, D(+) glucosamine, D mannosamine, and D galactosamine with 10 to 3000 mg of amino acid consisting of any combination of, or any one of, the group of amino acid consisting of glutamine, lysine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and taurine.

Hair Growth

It has been demonstrated that certain materials are useful in retarding loss of hair. A number of proprietary products are available commercially which claim some success both in reducing hair loss and in restoring hair. They are applied externally and it is thought that they serve as neuroreceptors at the surface of hair follicle cells. The material of the invention is beta carotene which, when introduced into glia may serve as a neurotransmitter to signal hair follicles to action. Tests demonstrate that when beta carotene is ingested with a material such as that described above that will cross the blood-brain barrier. In one test, thirty mg of beta carotene taken daily for forty five days with 2500 mg of fructose in 250 cc of orange juice resulted in arrest of hair loss at the user's hairline and growth of new hair in the area of his crown. The subject, whose natural hair color was black, turning grey, had virtually only black head and body hair at the end of the forty five day test.

Tests indicate that the base material, sugar and amino acid in the quantities described above are effective to result in transportation of beta carotene, and other substances for about one half hour. Whether that is because the base material remains in the blood for that period or produces an effect in

the brain that lasts for that period is not known. However, because of that effect the beta carotene need not be ingested with the base material but can be ingested at a point removed in time. There appears to be no critical dosage of beta carotene. Because it is ingested and because the recommended daily amount is 5000 IU, that quantity is now considered to be the preferred minimum. No acceleration of hair restoral has been observed when the amount of beta carotene is increased above 20,000 IU so that is now considered to be the upper limit above which increased cost provides no benefit.

Application to Drunkenness

It has been demonstrated that the material provided by the invention is useful in restoring motor functions in individuals who have impaired motor functions as a consequence of the ingestion of alcohol and that the restoration occurs in a matter of seconds. When practicing the invention in connection with drunkenness, it is now preferred that the sugar and amino acid combination be provided in powdered rather than in capsule or pill form to minimize the possibility of choking by an inebriated user. Also, it is preferred to incorporate something to flavor the mixture and enhance its palatability. That can be done by adding one or both of an artificial flavoring material and a dried and powdered fruit in crystalline or solid form which has a desired flavor and, in addition, serves as a source of amino acid. Orange and lemon solids or crystals are examples.

An excessive amount of any of the listed sugars can cause nausea, heat sensation, flushing, and ringing of the ears. The degree of drunkenness to be overcome and the amount required in the practice of the invention depends in part on the amount of alcohol that was ingested. There is a level of alcohol intake below which the drinker does not require the invention. In terms of amount of sugar, that level is about 2.5 grams. More than 6 grams of sugar may produce the adverse side effects listed above and is not required to produce the sobering effect. Thus the range of sugar per serving is about 2.5 to 6 grams. When prepackaged, 2.5 to 3 grams per package is preferred. A drinker who needs more than 3 grams, may be given two packages.

Other Research and Treatment Applications

The invention provides novel materials for research into the understanding and/or treatment and the possible treatment of disorders where an attempt is to be made to transport chemical substances past the blood-brain barrier. To realize that

objective, the invention comprises the combination of a material that will pass the blood-brain barrier and any non-carcinogenic material having apparent utility in connection with the treatment of the disorder being investigated. In preferred form the material that will pass the blood-brain barrier is a sugar and amino acid combination as described above and the added material is a vitamin or mineral or electrolyte whose effect is to be tested. Some examples of specifically preferred materials are listed below.

Other Examples

The following several examples are intended to describe mid range proportions and doses of test and treatment materials for human subjects. Stripped of quantity figures, they are examples of substance combinations that will pass the blood brain barrier in the testing and treatment of higher order animals and humans.

Example 2 For research into and or treatment of baldness:

the sugar and amino acid combination described in example 1 above; and

165 to 15000 IU and preferably about 30 mg beta carotene or xanthophyll.

Example 3 For research into and or treatment of Alzheimer Disease:

the sugar and amino acid combination described in example 1 above:

10 mg to 12,000 mg and preferably about 2500 mg of lecithin;

120 to 2500 mg and preferably about 1000 mg of calcium;

5 to 1000 mg and preferably about 10 mg somatostatin;

5 to 1000 mg and preferably about 10 mg vasopressin; and

1 to 500 mg and preferably about 10 mg acetyl-L-carnitine.

Example 4 For research into and or treatment of Huntington's disease:

the sugar and amino acid combination described in example 1 above;

2.5 to 1000 mg and preferably about 1000 GABA; and

5 to 1000 mg and preferably about 10 mg dynorphin.

Example 5 For research into and or treatment of depression, insomnia or chronic pain:

the sugar and amino acid combination described in example 1 above including 2 to 750 mg, and preferably about 500 mg, L-tryptophan; and

10 mg to 12000 mg and preferably about 2500 mg lecithin or 13 to 5000 mg and preferably about 1000 mg choline;

0.2 to 125 mg and preferably about 1.5 mg

thiamine;

0.2 to 125 mg and preferably about 2 mg pyridoxine; and

16 to 25 mg and preferably about 20 mg niacin.

Example 6 For research into and or treatment of addiction to alcohol, heroine, cocaine or nicotine, anxiety, bulimia, anorexia nervosa, phobia, panic disorder, obsessive compulsive disorder, and attention deficient hyperactivity disorder;

the sugar and amino acid combination described in example 1 above including 15 to 5700 mg and preferably about 2500 mg of one or a combination of L-arginine and hydroxyproline.

Example 7 For research into and or treatment of brain damage, stroke, spinal cord injury and autism:

the sugar and amino acid combination described in example 1 above;

10 mg to 12000 mg, and preferably about 2400 mg, lecithin; and

0.5 to 50 mg, and preferably about 10 mg, Nerve Growth Factor (NGF) polypeptide.

Example 8 For research into and or treatment of muscular dystrophy, Lou Gehrig's disease and cerebral palsy:

the sugar and amino acid combination described in example 1 above including 6 to 2500 mg and preferably about 550 mg methionine;

2.5 to 920 mg and preferably about 550 mg cystine;

120 to 2500 mg and preferably about 1000 mg calcium;

155 to 2350 mg and preferably about 2000 mg potassium chloride or 155 to 4000 mg and preferably about 2500 mg potassium gluconate;

1 to 5 mg and preferably about 3 mg boron;

60 to 800 mg and preferably about 120 mg phosphorus;

13 to 5000 mg and preferably about 1000 mg chlorine;

50 to 5800 mg and preferably about 2500 sodium chloride; and

5 to 1000 mg and preferably about 10 mg dynorphin.

Example 9 For research into and or treatment of osteoporosis or bone damage:

the sugar and amino acid combination described in example 1 above;

155 to 2350 mg and preferably about 2000 mg potassium chloride or 155 to 4000 mg and preferably about 2500 mg potassium gluconate;

60 to 1200 mg and preferably about 800 mg phosphorus;

50 to 5800 mg and preferably 2500 mg sodium chloride;

14 to 1000 IU and preferably about 400 IU vitamin D;

50 to 18000 mg and preferably about 60 mg vitamin C;

1 to 5 mg and preferably about 3 mg boron; and

120 to 2500 mg and preferably about 1500 mg calcium carbonate.

Example 10 For research into and or treatment of incontinence and heart muscle disorders:

the sugar and amino acid combination described in example 1 above;

155 to 2350 mg and preferably about 2000 mg potassium chloride or 155 to 4000 mg and preferably about 2500 mg potassium gluconate;

120 to 2500 mg and preferably about 1000 mg calcium;

14 to 1000 IU and preferably about 400 IU vitamin D; and

50 to 18000 mg and preferably about 60 mg vitamin C.

Example 11 For research into and or treatment of cancers and the production of hematopoietic stem cells, T-cells and B-cells:

the sugar and amino acid combination described in example 1 above;

25 to 35 mg and preferably about 30 mg beta carotene;

180 to 10000 IU and preferably about 5000 IU of vitamin A;

18 to 400 IU and preferably about 30 IU vitamin E;

2 to 200 mcg and preferably about 10 mcg selenium;

50 mg to 18 grams and preferably about 1 gram of vitamin C;

3 mcg to 500 mcg and preferably about 50 mcg of B-12;

155 to 2500 mg and preferably about 1500 mg tricalcium phosphate; and

either 155 to 2350 mg and preferably 1500 mg potassium chloride or 155 to 4000 mg and preferably 1500 mg potassium glutinate.

Example 12 For research into and or treatment of poor memory, stress, headache and stuttering:

the sugar and amino acid combination described in example 1 above; and

10 to 12000 mg and preferably about 2500 mg lecithin or choline.

Example 13 For research into and or treatment of pain, hypertension, cardiac arrhythmias, Parkinson's Disease, pre-menstrual syndrome (PMS), attention deficient disorder and shock, in combination:

the sugar and amino acid combination described in example 1 above which includes about 1000 mg or more of L-tryptophan; and

10 to 12000 mg and preferably about 2500 mg lecithin or choline.

Example 14 For research into and or treatment of

acne, psoriasis, lupus, eczema and wrinkles:

the sugar and amino acid combination described in example 1 above;

180 to 10000 IU and preferably about 5000 IU vitamin A;

25 to 35 mg and preferably about 30 mg beta carotene;

120 to 2500 mg and preferably about 1000 mg calcium;

120 to 2500 mg and preferably about 1000 mg omega 3; and

120 to 2500 mg and preferably about 1000 mg omega 6.

Example 15 For research into and or treatment of manic depression:

the sugar and amino acid combination described in example 1 above including 2 to 2000 mg and preferably about 1000 mg tryptophan;

1 to 1000 mg endorphin; and

1 to 1000 mg enkephalin.

Example 16 For research into and or treatment of the general symptoms of aging:

2 to 4 grams of one or more of the sugars listing in example 1 above;

the recommended daily requirement (RDA) of vitamins A, B-1, niacin, B-2, B-6, B-12, C, D, E, D-biotin, pathothenic acid and folic acid;

about 40 to 50 mg vitamin K;

about 1000 mg beta carotene;

the recommended daily requirement of the minerals: calcium, phosphorus, iodine, iron, magnesium, copper, and zinc;

about 5 to 15 mg of each of chromium, selenium, and molybdenum;

2 to 3 mg manganese;

35 to 40 mg potassium;

30 to 40 mg chloride;

2 to 3 grams lecithin;

400 to 2000 mg choline;

the recommended daily requirement of the amino acids: lysine, histidine, leucine, methionine, phenylalanine, tryptophan, tyrosine and valine;

about 1 gram of each of the amino acids glutamine, aspartic acid, glutamic acid, threonine, proline and serine;

15 to 6000 mg and preferably about 800 mg arginine;

1 to 500 mg and preferably about 250 mg asparagine;

11 to 500 mg and preferably about 400 mg glycine;

2 to 900 mg and preferably about 90 mg cysteine;

1 to 500 mg and preferably about 500 mg taurine;

120 to 2500 mg and preferably about 1000 mg omega 3; and

120 to 2500 mg and preferably about 1000 mg

omega 6.

Example 17 For research into and or treatment of diabetes:

the sugar and amino acid combination described in example 1 above including 2 to 2000 mg and preferably about 1000 mg tryptophan and 11 to 4100 mg and preferably 1000 mg tyrosine;

120 to 2500 mg and preferably about 1000 mg omega 3; and

120 to 2500 mg and preferably about 1000 mg omega 6.

Example 18 For research into and treatment of abnormal or undesirable blood chemistry particularly in relation to cholesterol and plasma, HDL and LDL the sugar and amino acid combination described in example 1 above;

500 to 6000 mg and preferably about 1000 mg of niacin; and

150 to 3000 mg and preferably about 1500 mg of oats, rice or apple fiber.

Example 19 For research into and or treatment of migraine headache and comatose condition:

the sugar and amino acid combination described in example 1 above which includes about 1000 mg or more of L-tryptophan; and

10 to 12000 mg and preferably about 2500 mg lecithin or choline.

Example 20 For ingestion by athletes in training, the upper range of the substances listed in Example 16 above.

Example 21 For research into and or treatment of jet lag and chronic throat congestion:

the sugar and amino acid combination described in example 1 above.

Example 22 For research into and or treatment of neuroses and anxiety without tranquilizers, paranoia, schizophrenia, mania and sleeping disorders:

the sugar and amino acid combination described in example 1 above in which the quantity of sugar is increased to 10 grams; and

10 grains of acetylsalicylic acid.

Example 23 For research into and or treatment of arthritis, rheumatism, multiple sclerosis, and other auto-immune diseases:

the sugar and amino acid combination described in example 1 above:

155 to 2500 mg and preferably about 1500 mg tricalcium phosphate;

120 to 2500 mg and preferably about 1000 mg omega 3; and

120 to 2500 mg and preferably about 1000 mg omega 6.

Example 24 For research into and or treatment of AIDS and AWS:

the sugar and amino acid combination described in example 1 above;

165 to 15000 IU and preferably about 5000 IU carotene or xanthophyll;

120 to 2500 mg and preferably about 1000 mg calcium;

155 to 2350 mg and preferably about 2000 mg potassium chloride or 155 to 4000 and preferably about 2500 mg potassium glutinate;

60 to 1200 mg and preferably about 800 phosphorus; and

5 to 30 mg of freeze dried acidophilus.

Example 25 For research into and or treatment of chronic fatigue syndrome:

the sugar and amino acid combination described in example 1 above:

120 to 2500 mg and preferably about 1000 mg calcium; and

155 to 2350 mg and preferably about 2000 mg potassium chloride or 155 to 4000 and preferably about 2500 mg potassium glutinate;

Claims

1. The combination of any one or more pure sugars selected from the group consisting of:

meso erythritol, zylithol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, myo-inositol, L(-) fructose, D(-) mannitol, sorbitol, D(+) glucose, D(+) arabinose, D(-) arabinose, cellobiose, D(+) maltose, D(+) raffinose, L(+) rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, L(-) Lyxose, D(+) glucosamine, D mannosamine, and D galactosamine; and

any one or more amino acids from the group consisting of glutamine, lysins, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glycine, histidine, leucine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, and taurine.

2. The material defined in claim 1 which includes from 400 to 3,000 mg of amino acid for each 2,500 mg of sugar, and which further comprises, for each 3,000 to 9,000 parts of that material, about:

25 to 35 parts of beta carotene or xanthophyll.

3. In combination: the material defined in claim 1 which includes from 400 to 3,000 mg of amino acid for each 2,500 mg of sugar, and which further comprises, for each 3,000 to 9,000 parts of that material, either:-

(A) about 10 to 12,000 parts of lecithin:

120 to 2,500 parts of calcium;

5 to 1,000 parts somatostatin;

5 to 1,000 parts vasopressin; and

1 to 500 parts acetyl-L-carnitine:- for research into and or treatment of Alzheimer disease,

OR

(B) about 2.5 to 1,000 parts GABA; and

5 to 1,000 parts dynorphin:- for research into and or treatment of Huntington's disease,

OR

(C) about 10 to 12,000 parts lecithin or 13 to 500 parts choline;

0.2 to 125 parts thiamine;

0.2 to 125 parts pyridoxine; and

16 to 25 parts niacin:- for research into and or treatment of depression, insomnia or chronic pain,

OR

(D) about 10 to 12,000 parts of lecithin; and

0.5 to 50 parts Nerve Growth Factor (NGF) polypeptide:- for research into and or treatment of brain damage, stroke, spinal cord injury, or autism,

OR

(E) about 155 to 2,350 parts potassium chloride or 155 to 4,000 parts potassium gluconate;

60 to 1,200 parts phosphorus;

50 to 5,800 parts of sodium chloride;

120 to 2,500 mg calcium carbonate;

14 to 1,000 IU vitamin D;

50 to 18,000 parts vitamin C; and

1 to 5 parts boron:- for research into and or treatment of osteoporosis or bone damage,

OR

(F) about 155 to 2,350 parts potassium chloride or 155 to 4,000 parts potassium gluconate;

120 to 2,500 parts calcium;

14 to 1,000 IU vitamin D; and

50 to 18,000 parts vitamin C:- for research into and or treatment of incontinence or heart muscle disorder,

OR

(G) about 10 to 12,000 parts lecithin or chorine:- for research into and or treatment of poor memory, stress, headache or stuttering,

OR

(H) about 500 to 6,000 parts of niacin:- for research into and or treatment of abnormal or undesirable blood chemistry particularly in relation to cholesterol and plasma. HDL and LDL.

4. The material defined in claim 1 which includes from 400 to 3,000 mg of amino acid for each 2,500 mg of sugar and either:-

(A) wherein the amino acid includes 15 to 5,700 parts of either or both of L-arginine and hydroxyproline:- for research into and or treatment of addiction to alcohol, heroine, cocaine or nicotine, bulimia, anorexia, phobia, panic disorder, obsessive compulsive disorder, attention deficit hyperactivity disorder or anxiety,

OR

(B) wherein the amino acid includes 6 to 2,500 mg of methionine, in combination with about:

2.5 to 920 parts of cystine;

120 to 2,500 parts calcium;

155 to 2,350 parts of potassium chloride or 155 to 4,000 parts potassium gluconate;

60 to 120 parts of phosphorus;

13 to 5,000 parts of chlorine;

50 to 5,800 parts of sodium chloride; and

5 to 1,000 parts of dynorphin:- for research into and or treatment of muscular dystrophy, Lou Gehrig's disease or cerebral palsy,

OR

(C) wherein the amino acid includes 2 to 2,000 mg L-tryptophan, in combination with about:

10 to 12,000 parts lecithin or chorine:- for research into and or treatment of pain, hypertension, cardiac arrhythmias, Parkinson's disease, pre-menstrual syndrome (PMS), or shock,

OR

(D) wherein the amino acid includes 2 to 5,000 of L-tryptophan, in combination with about:

1 to 1,000 parts endorphin; and

1 to 1,000 parts enkephalin:-for research into and or treatment of manic depression.

6. In combination:

the sugar and amino acid combination described in example 1 above and either:-

(A) 2 to 35 mg and preferably about 30 mg beta carotene;

180 to 10,000 IU and preferably about 5,000 IU of vitamin A;

18 to 400 IU and preferably about 30 IU vitamin E;

2 to 200 mcg and preferably about 10 mcg selenium;

50 mg to 18 grams and preferably about 1 gram of vitamin C;

3 mcg to 500 mcg and preferably about 50 mcg of B-12;

155 to 2,500 mg and preferably about 1,500 mg tricalcium phosphate; and

155 to 2,350 mg and preferably 1,500 mg potassium chloride:- for research into and or treatment of cancers and production of hematopoietic stem cells, T-cells and B-cells,

OR

(B) 180 to 10,000 IU and preferably about 5,000 IU vitamin A;

25 to 35 mg and preferably about 30 mg beta carotene;

120 to 2,500 mg and preferably 1,000 mg calcium;

120 to 2,500 mg and preferably about 1,000 mg omega 3; and

120 to 2,500 mg and preferably 1,000 mg omega 6:- for research into and or treatment of acne, psoriasis, eczema, lupus, and wrinkles,

OR

(C) 10 grains of acetylsalicylic acid and in which the quantity of sugar is increased to 10 grams:- for research into and or treatment of neuroses and anxiety without tranquillisers, schizophrenia, paranoia, mania and sleeping dis-

orders,

OR

(D) 155 to 2,500 mg and preferably about 1,500 mg tricalcium phosphate;

120 to 2,500 mg and preferably about 1,000 mg omega 3; and

120 to 2,500 mg and preferably about 1,000 mg omega 6:- for research into and or treatment of arthritis, rheumatism, multiple sclerosis, and other auto-immune diseases,

OR

(E) 165 to 15,000 IU and preferably about 5,000 IU carotene or xanthophyll;

120 to 2,500 mg and preferably about 1,000 mg calcium;

155 to 2,350 mg and preferably about 2000 mg potassium chloride or 155 to 4,000 and preferably about 2,500 mg potassium glutinate;

60 to 1,200 mg and preferably about 800 phosphorus; and

5 to 30 mg of freeze dried acidophilus:- for research into and or treatment of AIDS and AWS,

OR

(F) 120 to 2,500 mg and preferably about 1,000 mg calcium; and

155 to 2,350 mg and preferably about 2,000 mg potassium chloride:-for research into and or treatment of chronic fatigue syndrome.

6. An athletic drink comprising:

2,000 to 4,000 parts of one or more pure sugars selected from the group consisting of meso erythritol, zylitol, D(+) galactose, D(+) lactose, D(-) xylose, dulcitol, myoinositol, L(-) fructose, D(-) mannitol, sorbitol, D(+) glucose, D(+) arabinose, D(-) arabinose, cellobiose, D(+) maltose, D(+) raffinose, L(+) rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, L(-) lyxose, D(+) glucosamine, D mannosamine, and D galactosamine;

the recommended daily requirement (RDA) of vitamins A, B-1, niacin, B-2, B-6, B-12, C, D, E, D-biotin, pathothenic acid and folic acid;

about 40 to 50 parts vitamin K;

about 1,000 parts beta carotene;

the recommended daily requirement of the minerals calcium, phosphorus, iodine, iron, magnesium, copper, and zinc;

about 5 to 15 parts of each of chromium, selenium, and molybdenum;

2 to 3 parts manganese;

35 to 40 parts potassium;

30 to 40 parts chloride;

2,000 to 3,000 parts lecithin;

400 to 2,000 parts choline;

the recommended daily requirement of the amino acids lysine, histidine, leucine, methionine,

phenylalanine, tryptophan, tyrosine and valine;

about 1,00 parts of each of the amino acids glutamine, aspartic acid, glutamic acid, threonine, proline and serine:

15 to 6,000 parts arginine;

1 to 500 parts asparagine;

11 to 400 parts glycine;

2 to 900 parts cysteine; and

1 to 500 parts taurine.

7. The material defined in claim 1 which includes from 400 to 3,000 mg of amino acid, including 2 to 750 mg L-tryptophan and 11 to 4,100 mg tyrosine, for each 2,500 mg of sugar, and which further comprises, for each 3,000 to 9,000 parts of that material, about:

10 to 12,000 mg of either, or a combination, lecithin or chorine:-for research into and or treatment of diabetes.

8. The material defined in claim 1 which includes from 400 to 3,000 mg of amino acid, including 500 to 1,500 mg L-tryptophan for each 2,500 mg of sugar;

10 to 12,000 mg and preferably about 2,500 mg lecithin or chorine:-for research into and or treatment of migraine headache or comatose condition.

9. For research into and treatment of the general symptoms of ageing:

4,000 parts of one or more pure sugars or pure amino sugars selected from the group consisting of meso erythritol, zylitol, D(+) galactose, D(+) lactose, D(+) xylose, dulcitol, myo-inositol, L(-) fructose D(-) mannitol, sorbitol, D(+) glucose, D(+) arabinose, D(-) arabinose, cellobiose, D(+) maltose, D(+) raffinose, L(+) rhamnose, D(+) melibiose, D(-) ribose, adonitol, D(+) arabitol, L(-) arabitol, D(+) fucose, L(-) fucose, D(-) lyxose, L(+) lyxose, L(-) lyxose, D(+) glucosamine, D mannosamine, and D galactosamine:

the recommended daily requirement (RDA) of vitamins A, B-1, niacin, B-2, B-6, B-12, C, D, E, D-biotin, pathothenic acid and folic acid;

about 50 parts vitamin K;

about 1,000 parts beta carotene;

the recommended daily requirement of the minerals: calcium, phosphorus, iodine, iron, magnesium, copper, and zinc:

about 15 parts of each of chromium, selenium, and molybdenum;

about 3 parts manganese;

about 40 parts potassium;

about 40 parts potassium or sodium chloride;

about 3,000 parts lecithin;

about 600 parts choline;

the recommended daily requirement of the amino acids: lysine, histidine, leucine, methionine, phenylalanine, tryptophan, tyrosine and valine;

about 1,000 parts of each of the amino acids

glutamine, aspartic acid, glutamic acid, threonine, proline and serine;

about 6,000 parts arginine;

about 500 parts asparagine;

about 400 parts glycine;

5

about 900 parts cysteine; and

about 500 parts taurine.

10. For research into and or treatment of jet lag and chronic throat congestion, in combination:

the sugar and amino acid combination described in example 1 above.

10

15

20

25

30

35

40

45

50

55

10



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 93 30 8852
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
X	WO-A-89 04165 (J.A. HAKLITCH) 18 May 1989 * the whole document *	1-10	A61K31/70 A61K31/195

X	DATABASE WPI Derwent Publications Ltd., London, GB; AN 91-112625 [16] & JP-A-3 052 810 (A.T. NAITO) * abstract *	1-10	

T	DATABASE WPI Derwent Publications Ltd., London, GB; AN 94-031720 [04] & JP-A-5 339 148 (A.T. NAITO) 21 December 1993 * abstract *	1-10	

X	DATABASE WPI Derwent Publications Ltd., London, GB; AN 85-162827 [27] & JP-A-60 094 075 (AJINOMOTO KK) * abstract *	1-10	

	-/--		
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present European patent application does not comply with the provisions of the European Patent Convention to such an extent that it is not possible to carry out a meaningful search into the state of the art on the basis of some of the claims</p> <p>Claims searched completely : Claims searched incompletely : Claims not searched : Reason for the limitation of the search:</p> <p>see sheet C</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		11 March 1994	Orviz Diaz, P
CATEGORY OF CITED DOCUMENTS			
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application I : document cited for other reasons ----- & : member of the same patent family, corresponding document	



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 93 30 8852

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	REYNOLDS, J.E.F. (ED.), 'MARTINDALE THE EXTRA PHARMACOPOEIA'. 29TH EDITION, 1989, THE PHARMACEUTICAL PRESS, LONDON. * page 1289 - page 1291 * ---	1-10	
X	BERKOW, R. (ED.), 'THE MERCK MANUAL OF DIAGNOSIS AND THERAPY'. 15TH EDITION, 1987, MERCK SHARP & DOHME RESEARCH LABORATORIES, RAHWAY, N.J., USA. * page 904 - page 911 * ---	1-10	
X	MICROMEDEX, INC., DENVER, COLORADO, VOL. 79, FILE DRUGDEX (R), DRUG EVALUATION MONOGRAPHS. * AMINO ACID SOLUTIONS * ---	1-10	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
X	MICROMEDEX, INC., DENVER, COLORADO, VOL. 79, FILE PDR (R) ON CCIS(R) * ALITRAQ * ---	1-10	
X	MICROMEDEX, INC., DENVER, COLORADO, VOL. 79, FILE PDR (R) ON CCIS(R) * PRO-HEPATONE * ---	1-10	
X	MICROMEDEX, INC., DENVER, COLORADO, VOL. 79, FILE PDR (R) ON CCIS(R) * TRI-LEAN * -----	1-10	



EP 93 30 8852

-C-

II) MEANINGFUL SEARCH NOT POSSIBLE OR INCOMPLETE SEARCH....

2. OBSCURITIES, INCONSISTENCIES, CONTRADICTIONS,...

In view of the extremely large number of combinations claimed, and in the absence of specific pharmacological examples, the search had to be limited to what appears to be the general inventive idea. (see Guidelines for Examination in the European Patent Office, Part. B, Chapter II.7, last sentence and Chapter III.3.7)